Clinical Trial Detail

NCT ID NCT02273973
Title Study of Neoadjuvant Letrozole + GDC-0032 Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements yes
Sponsors Genentech, Inc.
Indications

Her2-receptor negative breast cancer

Therapies

Taselisib

Age Groups: adult

Additional content available in CKB BOOST